He participated in a competition to explain his Alzheimer study in a way that resonates with those who stand to benefit from it.

A competition that asks master's and Ph.D. candidates to distill their work into a three-minute presentation has them honing ...

Amer, S.A.A., Elzarrug, H.K.H.A. and Elfakhri, A.A. (2025) Sociodemographic and Clinical Characteristics of Participants Attended Glaucoma Screening Week in Benghazi 2023. Open Access Library Journal, ...

A typical zongo boy hardly takes a courageous move of responding to a “Call for Abstract and academic paper presentation” at ...

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poste ...

TURKU, FI / ACCESS Newswire / March 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) New analysis and biomarker data strengthens understanding of bexmarilimab's potentialTURKU, FINLAND - Faron ...

Samman, A. and Babi, A. (2025) Pulmonary Septic Emboli Following Endocarditis: A Case Report. Open Journal of Clinical ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic ...

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients ...

BioAtla has two abstracts accepted for poster presentations at major oncology conferences, enhancing visibility in the scientific community. The presentations will feature cutting-edge research on ...

This abstract is a sub-study of the TIGeR-PaC clinical trial. The combination product candidate (IAG), which is enabled by the FDA-cleared RenovoCath device, is currently under investigation and ...

This abstract is a sub-study of the TIGeR-PaC clinical trial. The combination product candidate (IAG), which is enabled by the FDA-cleared RenovoCath device, is currently under investigation and has ...